Biotech Values

[biocqr]

Re: AHAC > Lots of hype but they do have POC, a huge market and a huge moat...

Arterial reconstruction with human bioengineered acellular blood vessels in patients with peripheral arterial disease

https://humacyte.com/wp-content/uploads/2020/11/2020.-Gutowski_JVS-Arterial-reconstruction-with-human-bioengineered.pdf

Results: Twenty HAVs were placed in the arterial, above-knee, femoral-to-popliteal position in patients with rest pain
(n ¼ 3) or symptomatic claudication (n ¼ 17). All HAVs functioned as intended and had no evidence of structural failure
or rejection by the recipient. No acute HAV infections were reported, but three surgical site infections were documented during the study period. Three non-HAV-related deaths were reported. One vessel developed a pseudoaneurysm after suspected iatrogenic injury during a balloon thrombectomy. No amputations of the HAV implanted limb occurred over the 2-year period, and no HAV infections were reported in approximately 34 patient-years of continuous patient follow-up.

Conclusions: Human tissue engineered blood vessels can be manufactured and readily available for peripheral arterial
bypass surgery. Early clinical experience with these vessels, in the arterial position, suggest that they are safe, have
acceptable patency, a low incidence of infection, and do not require the harvest of autologous vein or any cells from the
recipient. Histologic examination of tissue biopsies revealed vascular remodeling and repopulation by host cells. This first in-man arterial bypass study supports the continued development of human tissue engineered blood vessels for arterial
reconstruction, and potential future expansion to clinical indications including vascular trauma and repair of other size appropriate peripheral arteries. (J Vasc Surg 2020;-:1-12.)
Keywords: Peripheral arterial disease; Arterial reconstruction; Bioengineered blood vessel; HAV